Literature DB >> 343024

Improved results in combination chemotherapy of head and neck cancer using a kinetically-based approach: a randomised study with and without adriamycin.

L A Price, B T Hill, A H Calvert, M Dalley, A Levene, E R Busby, M Schachter, H J Shaw.   

Abstract

One hundred and seventeen patients with advanced squamous cell carcinoma of the head and neck were randomised between two combination schedules, one with and the other without adramycin. Responses (more than 50% tumor regression) were 67% overall with 63% responding to the combination without adriamycin and 82% responding to the schedule containing it. The increase in response rate seen with the addition of adriamycin is not statistically significant. Prior radiotherapy reduced the likelihood of response to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 343024     DOI: 10.1159/000225250

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  7 in total

Review 1.  Current impact of adjuvant chemotherapy in resectable cancer.

Authors:  A Rossi; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Update in cancer chemotherapy: head and neck cancer, Part 2.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-11       Impact factor: 1.798

Review 3.  Head and neck cancer: guidelines for chemotherapy.

Authors:  G Catimel
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

Review 5.  Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.

Authors:  M al-Sarraf
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

6.  Phase-II study of cis-diammine-dichloro platinum (cis-platinum), bleomycin and methotrexate for advanced squamous cell carcinoma of head and neck.

Authors:  P Espana; F Smith; J Abrams; D Haidak; W Ueno; P Woolley; P Schein
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors.

Authors:  C Focan; R Olivier; S Le Hung; R Bays; J J Claessens; H Debruyne
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.